Besthof Robert
Known title: Chief Comm. & Patient OfficerCIK: 0001864650
Associated companies
Transaction History
| NRXP | ▼ Sell | Open Market | 40,000 | $470K | 9/15/2021 | View on chart |
| NRXP | ▲ Buy | Option Exercise | 63,710 | $13K | 8/16/2021 | View on chart |
| NRXP | ▼ Sell | Open Market | 40,000 | $470K | 9/15/2021 | View on chart |
| NRXP | ▲ Buy | Option Exercise | 63,710 | $13K | 8/16/2021 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Ono Pharmaceutical Rallies 13.9% Amid NRX Partnership
Ono Pharmaceutical shares rose 13.9%, a move likely tied to its ongoing relationship with NRX Pharmaceuticals. This partner's stock performance often influences sentiment around NRX, which is currently trading near its 52-week low. The significant gain in the partner's stock highlights the continued relevance of their collaboration in the market.
Ono Pharmaceutical Rallies 13.9% Amid NRX Partnership. Ono Pharmaceutical shares rose 13.9%, a move likely tied to its ongoing relationship with NRX Pharmaceuticals. This partner's stock performance often influences sentiment around NRX, which is currently trading near its 52-week low. The significant gain in the partner's stock highlights the continued relevance of their collaboration in the market.